Fairvalue-Calculator Fairvalue-Calculator
EN DE

COSCIENS Biopharma Inc (CSCI) Fair Value & Analysis

Healthcare · US · Market cap $8.6M

Price$2.98
Fair Value$18.64
Upside+525.5%
Quality92/100
Evidence: Low Range $13.98 – $23.30

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

COSCIENS Biopharma Inc (CSCI) currently trades at $2.98, while our model-based Fair Value estimate is $18.64 — implying the stock looks roughly 525.5% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its pro…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is COSCIENS Biopharma Inc (CSCI) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $18.64 versus a price of $2.98 — about +526% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CSCI?
Our 21-model fair value for COSCIENS Biopharma Inc is $18.64 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.98.
What is the quality score of CSCI?
COSCIENS Biopharma Inc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.